Global Ustekinumab Injection Market Strategic Research Report

Scope of the Report

The global Ustekinumab Injection market size is predicted to grow from US$ 15,590 million in 2025 to US$ 23,760 million in 2032; it is expected to grow at a CAGR of 6.3% from 2026 to 2032.

Ustekinumab Injection is a formulation containing ustekinumab as the active ingredient, which is a fully human IgG1κ monoclonal antibody. It works by specifically binding to the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby blocking their interaction with receptors and inhibiting the activation of associated inflammatory signaling pathways. This injectable medication is commonly indicated for the treatment of immune-mediated diseases such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. In 2024, the global production volume of ustekinumab injection was 3.9 million syringes, with an average price of USD 3,852 per syringe.

Market Overview

The ustekinumab market has maintained steady growth in recent years, driven by increasing demand from patients for effective and low-frequency dosing regimens. Growth is observed not only in established indications but also supported by clinical expansion into new therapeutic areas and the gradual introduction of biosimilars, contributing to overall market development.

Regional Market Landscape

Globally, the United States accounts for 50% of the market, Europe for 20%, Asia for 15%, and other regions for 15%, reflecting a market structure centered on North America and Europe, while the Asian market is rapidly penetrating and gradually forming a strong growth momentum.

Key Manufacturers and Industry Competition

The originator maintains a dominant position worldwide, but competition has intensified with the expiration of patents and the entry of biosimilars. Multiple international and regional companies are competing in the development, production, and commercialization of both originator and biosimilar products, while collaboration and licensing strategies are used to optimize market positioning.

Technological Trends and Innovation Directions

Technological innovation is primarily focused on high-concentration formulations and convenient administration methods, alongside optimization of biosimilars and research into combination therapy strategies. These innovations improve treatment adherence and provide technical support for expansion into new indications, facilitating broader clinical adoption.

Policy and Industry Development Drivers

Supportive healthcare policies and accelerated biosimilar approvals are key drivers of market growth, alongside increasing patient acceptance of innovative therapies. Regulatory optimization and industry guidance together promote the market’s standardization and scale expansion.

Future Outlook

Looking ahead, the ustekinumab market is expected to maintain steady growth amid intensified competition, with potential increases in market concentration. Expansion into new indications and personalized therapies will be major growth drivers, while technological innovation, regional penetration, and policy support will collectively shape the future market landscape.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Ustekinumab Injection market?

What factors are driving Ustekinumab Injection market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Ustekinumab Injection market opportunities vary by end market size?

How does Ustekinumab Injection break out by Type, by Application?

This report presents a comprehensive overview of the global Ustekinumab Injection market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Original Drug
• Biosimilars

Segment by Application

• Plaque Psoriasis
• Psoriatic Arthritis
• Crohn’s Disease
• Ulcerative Colitis
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Ustekinumab Injection market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact